Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GS-5745 in moderately to severely active Crohn's disease
2015-001249-10Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing GS-5745 with Placebo (2 arms). Primary endpoint: Co-primary efficacy endpoints. Started Aug 2015; status: completed.
02
Drugs
andecaliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-001249-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001249-10.